Absci Corporation, the drug and target discovery expanding the therapeutic potential of proteins, has entered into a research collaboration with Merck, using Absci’s AI-powered Integrated Drug Creation Platform.   Under the collaboration, Absci will deploy its Bionic Protein non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. In addition, Merck has the option to nominate up to three t...